Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2012, Article ID 560836, 8 pages
http://dx.doi.org/10.1155/2012/560836
Review Article

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons

1Department of Psychiatry, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si 463-712, Gyeonggi-do, Republic of Korea
2Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan 70428, Taiwan
3Department of Psychiatry, Chonbuk National University Medical School, 567 Baekje-daero, Deokjin-gu, Jeonju-si 561-756, Jeollabuk-do, Republic of Korea
4Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, 20 Geonjiro, Deokjin-gu, Jeonju-si 561-712, Jeollabuk-do, Republic of Korea

Received 13 May 2012; Accepted 22 May 2012

Academic Editor: Eduard Parellada

Copyright © 2012 Borah Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Molina, J. Sanz, F. Sarramea, C. Benito, and T. Palomo, “Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients,” Psychiatry Research, vol. 131, no. 1, pp. 45–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Lieberman, “Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia,” Journal of Clinical Psychiatry, vol. 60, supplement 12, pp. 9–12, 1999. View at Google Scholar · View at Scopus
  3. W. Cahn, H. E. Hulshoff Pol, E. B. Lems et al., “Brain volume changes in first-episode schizophrenia: a 1-year follow-up study,” Archives of General Psychiatry, vol. 59, no. 11, pp. 1002–1010, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. B. C. Ho, N. C. Andreasen, P. Nopoulos, S. Arndt, V. Magnotta, and M. Flaum, “Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia,” Archives of General Psychiatry, vol. 60, no. 6, pp. 585–594, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Sun, G. W. Stuart, M. Jenkinson et al., “Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study,” Molecular Psychiatry, vol. 14, no. 10, pp. 976–986, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Lieberman, J. M. Alvir, A. Koreen et al., “Psychobiologic correlates of treatment response in schizophrenia,” Neuropsychopharmacology, vol. 14, no. 3, supplement, pp. 13S–21S, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Birchwood, P. Todd, and C. Jackson, “Early intervention in psychosis: the critical period hypothesis,” British Journal of Psychiatry, vol. 172, no. 33, supplement, pp. 53–59, 1998. View at Google Scholar · View at Scopus
  8. J. A. Lieberman, D. Perkins, A. Belger et al., “The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches,” Biological Psychiatry, vol. 50, no. 11, pp. 884–897, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Robinson, M. G. Woerner, J. M. Alvir et al., “Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder,” Archives of General Psychiatry, vol. 56, no. 3, pp. 241–247, 1999. View at Google Scholar · View at Scopus
  10. T. S. S. R. Group, “The Scottish first episode schizophrenia study VIII. Five-year follow-up: clinical and psychosocial findings,” British Journal of Psychiatry, vol. 161, pp. 496–500, 1992. View at Google Scholar · View at Scopus
  11. P. Thieda, S. Beard, A. Richter, and J. Kane, “An economic review of compliance with medication therapy in the treatment of schizophrenia,” Psychiatric Services, vol. 54, no. 4, pp. 508–516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. J. Weiden and M. Olfson, “Cost of relapse in schizophrenia,” Schizophrenia Bulletin, vol. 21, no. 3, pp. 419–429, 1995. View at Google Scholar · View at Scopus
  13. D. G. Robinson, M. G. Woerner, J. M. Alvir, R. M. Bilder, G. A. Hinrichsen, and J. A. Lieberman, “Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder,” Schizophrenia Research, vol. 57, no. 2-3, pp. 209–219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Verdoux, J. Lengronne, F. Liraud et al., “Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects,” Acta Psychiatrica Scandinavica, vol. 102, no. 3, pp. 203–210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. E. L. Coldham, J. Addington, and D. Addington, “Medication adherence of individuals with a first episode of psychosis,” Acta Psychiatrica Scandinavica, vol. 106, no. 4, pp. 286–290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Kane, “Review of treatments that can ameliorate nonadherence in patients with schizophrenia,” Journal of Clinical Psychiatry, vol. 67, supplement 5, pp. 9–14, 2006. View at Google Scholar · View at Scopus
  17. T. R. Argo, M. L. Crimson, A. L. Miller et al., “The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia,” The Texas Department of State Health Services, 2007.
  18. P. J. Weiden, N. R. Schooler, J. C. Weedon, A. Elmouchtari, A. Sunakawa, and S. M. Goldfinger, “A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome,” Journal of Clinical Psychiatry, vol. 70, no. 10, pp. 1397–1406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Kim, S. H. Lee, T. K. Choi et al., “Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 5, pp. 1231–1235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Heres, J. Hamann, W. Kissling, and S. Leucht, “Attitudes of psychiatrists toward antipsychotic depot medication,” Journal of Clinical Psychiatry, vol. 67, no. 12, pp. 1948–1953, 2006. View at Google Scholar · View at Scopus
  21. M. X. Patel, P. M. Haddad, I. B. Chaudhry, S. McLoughlin, and A. S. David, “Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years,” Journal of Psychopharmacology, vol. 24, no. 10, pp. 1473–1482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Jaeger and W. Rossler, “Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists,” Psychiatry Research, vol. 175, no. 1-2, pp. 58–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. H. Osborne, A. Dalton, J. Hertel, R. Schrover, and D. K. Smith, “Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study,” Health and Quality of Life Outcomes, vol. 10, article 35, 2012. View at Publisher · View at Google Scholar
  24. E. Parellada, R. Andrezina, V. Milanova et al., “Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable,” Journal of Psychopharmacology, vol. 19, no. 5, supplement, pp. 5–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Parellada, “Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations,” Psychopharmacology Bulletin, vol. 40, no. 2, pp. 82–100, 2007. View at Google Scholar · View at Scopus
  26. R. Emsley, P. Oosthuizen, L. Koen, D. J. H. Niehaus, R. Medori, and J. Rabinowitz, “Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection,” International Clinical Psychopharmacology, vol. 23, no. 6, pp. 325–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Emsley, P. Oosthuizen, L. Koen, D. J. Niehaus, R. Medori, and J. Rabinowitz, “Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies,” Clinical Therapeutics, vol. 30, no. 12, pp. 2378–2386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Napryeyenko, B. Burba, G. Martinez et al., “Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures,” Journal of Clinical Psychopharmacology, vol. 30, no. 2, pp. 200–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Dubois, J. Megens, C. Mertens et al., “Long-acting risperidone in early-episode schizophrenia,” Acta Psychiatrica Belgica, vol. 111, no. 1, pp. 9–21, 2011. View at Google Scholar
  30. S. H. Lee, T. K. Choi, S. Suh et al., “Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection,” Psychiatry Research, vol. 175, no. 3, pp. 195–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Rabinowitz, O. Napryeyenko, B. Burba et al., “Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable,” Journal of Clinical Psychopharmacology, vol. 31, no. 1, pp. 75–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Bartzokis, P. H. Lu, C. P. Amar et al., “Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory,” Schizophrenia Research, vol. 132, no. 1, pp. 35–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. E. Adams, M. K. Fenton, S. Quraishi, and A. S. David, “Systematic meta-review of depot antipsychotic drugs for people with schizophrenia,” British Journal of Psychiatry, vol. 179, pp. 290–299, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Rosenheck, J. H. Krystal, R. Lew et al., “Long-acting risperidone and oral antipsychotics in unstable schizophrenia,” The New England Journal of Medicine, vol. 364, no. 9, pp. 842–851, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Leucht, S. Heres, J. M. Kane, W. Kissling, J. M. Davis, and S. Leucht, “Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials,” Schizophrenia Research, vol. 127, no. 1–3, pp. 83–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Heres, T. Reichhart, J. Hamann, R. Mendel, S. Leucht, and W. Kissling, “Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia,” European Psychiatry, vol. 26, no. 5, pp. 297–301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Pereira and R. Pinto, “A survey of the attitudes of chronic psychiatric patients living in the community toward their medication,” Acta Psychiatrica Scandinavica, vol. 95, no. 6, pp. 464–468, 1997. View at Google Scholar · View at Scopus
  38. B. Svedberg, G. Backenroth-Ohsako, and K. Lützén, “On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication,” International Journal of Mental Health Nursing, vol. 12, no. 2, pp. 110–118, 2003. View at Google Scholar · View at Scopus
  39. J. Tiihonen, J. Haukka, M. Taylor, P. M. Haddad, M. X. Patel, and P. Korhonen, “A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia,” American Journal of Psychiatry, vol. 168, no. 6, pp. 603–609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Viala, F. Cornic, and M. Vacheron, “Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia,” Schizophrenia Research and Treatment, vol. 2012, Article ID 368687, 5 pages, 2012. View at Publisher · View at Google Scholar
  41. M. Álvarez-Jiménez, C. González-Blanch, B. Crespo-Facorro et al., “Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal,” CNS Drugs, vol. 22, no. 7, pp. 547–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. M. Francey, B. Nelson, A. Thompson et al., “Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention,” Schizophrenia Research, vol. 119, no. 1–3, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. L. Kelly, R. R. Conley, and W. T. Carpenter, “First-episode schizophrenia: a focus on pharmacological treatment and safety considerations,” Drugs, vol. 65, no. 8, pp. 1113–1138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Aggarwal, S. Dhawan, and S. L. Harikumar, “Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine,” Pharmaceutical Development and Technology, vol. 2011, Article ID 108374, 2011. View at Publisher · View at Google Scholar
  45. G. Aggarwal, S. Dhawan, and S. L. Harikumar, “Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone,” Drug Development and Industrial Pharmacy, vol. 2012, Article ID 036390, 2012. View at Publisher · View at Google Scholar
  46. S. Priebe, A. Burton, D. Ashby et al., “Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients—a cluster randomised controlled trial (FIAT),” BioMedCentral Psychiatry, vol. 9, article 61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Claassen, “Financial incentives for antipsychotic depot medication: ethical issues,” Journal of Medical Ethics, vol. 33, no. 4, pp. 189–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. A. F. Lehman, J. A. Lieberman, L. B. Dixon et al., “Practice guideline for the treatment of patients with schizophrenia, second edition,” American Journal of Psychiatry, vol. 161, no. 2, supplement, pp. 1–56, 2004. View at Google Scholar
  49. C. P. Association, “Clinical practice guidelines. Treatment of schizophrenia,” Canadian Journal of Psychiatry, vol. 50, no. 13, supplement 1, pp. 7S–57S, 2005. View at Google Scholar
  50. J. M. Kane and C. Garcia-Ribera, “Clinical guideline recommendations for antipsychotic long-acting injections,” British Journal of Psychiatry, vol. 195, supplement, pp. S63–S67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. T. R. Barnes and Schizophrenia Consensus Group of British Association for Psychopharmacology, “Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology,” Journal of Psychopharmacology, vol. 25, no. 5, pp. 567–620, 2011. View at Publisher · View at Google Scholar · View at Scopus